Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health Inc (NASDAQ: JAGX) delivers innovative plant-based therapeutics for gastrointestinal health across human and animal populations. This news hub provides investors and healthcare professionals with essential updates about the company’s clinical developments, regulatory milestones, and sustainable pharmaceutical innovations.
Access official press releases and verified news covering key areas including FDA approvals for Mytesi® (crofelemer), veterinary health product developments like Canalevia™, clinical trial progress, and strategic partnerships. Our curated collection ensures timely updates on JAGX’s advancements in non-opioid anti-secretory treatments and ecological sourcing practices.
Discover updates across multiple categories: new product launches, research collaborations, financial disclosures, intellectual property developments, and sustainability initiatives. Each update is vetted for accuracy, providing reliable insights into Jaguar Health’s progress in addressing chronic diarrhea conditions and neglected gastrointestinal disorders.
Bookmark this page for streamlined access to Jaguar Health’s latest developments. Check back regularly for updates on their unique approach to combining traditional botanical knowledge with modern pharmaceutical science through subsidiaries like Napo Pharmaceuticals.
Jaguar Health (NASDAQ:JAGX) announced that preliminary results from an ongoing pediatric trial of crofelemer, their plant-based anti-secretory drug, will be presented at the April 2025 ELITE PED-GI Congress in Abu Dhabi. The study focuses on treating microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF).
Crofelemer has received Orphan Drug Designation from both FDA and EMA for these conditions. The proof-of-concept study evaluates crofelemer's potential to improve stool formation, enhance nutrient absorption, and reduce total parenteral nutrition (TPN) needs in patients. Currently, there are no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea.
Positive results could potentially qualify crofelemer for the EMA's PRIME program and FDA's Breakthrough Therapies program, expediting development and review processes. The study is being conducted at Sheikh Khalifa Medical City under Dr. Mohamad Miqdady's leadership.
Jaguar Health (NASDAQ:JAGX) announced significant results from their Phase 3 OnTarget study focusing on Mytesi (crofelemer) for cancer therapy-related diarrhea. The study's prespecified subgroup analysis of breast cancer patients showed statistically significant results, despite the trial not meeting its primary endpoint across all tumor types.
The company has secured a Type C Meeting with the FDA in Q2 2025 to discuss potential approval pathways for crofelemer in breast cancer patients. The trial included 183 breast cancer patients out of 287 total participants. The results will be presented at the MASCC Annual Meeting in Seattle (June 26-28, 2025).
Additionally, a second late-breaker abstract on oral mucositis in cancer patients has been accepted for presentation at the same MASCC meeting, highlighting the company's broader focus on cancer supportive care.
Napo Pharmaceuticals, a Jaguar Health company (NASDAQ:JAGX), is showcasing Gelclair, their FDA-approved oral mucositis prescription product, at the Oncology Nursing Society Congress in Denver. Gelclair represents the company's third commercialized prescription product and marks their expansion into cancer-related supportive care.
Gelclair is a protective gel that provides pain relief for oral mucositis ('chemo mouth'), a common side effect affecting up to 40% of chemotherapy patients and 90% of head and neck cancer patients receiving chemo and radiotherapy. The product uniquely offers soothing relief without stinging or burning effects.
The company's core target audiences are head and neck cancer patients (71,110 US cases in 2024) and bone marrow transplant patients (approximately 23,000 annually). Notably, oral mucositis has been identified as the most significant adverse event in oncology by the National Comprehensive Cancer Network task force, with 19% of head and neck cancer patients requiring hospitalization due to high-grade mucositis.
Jaguar Health (NASDAQ:JAGX) has announced new employee inducement grants effective April 3, 2025. The company granted restricted stock units (RSUs) to six new employees: two employees received 3,600 RSUs each with three-year vesting periods, while four employees received 600 or 100 RSUs each with one-year vesting schedules.
Additionally, the company granted incentive stock options to a seventh employee for the purchase of up to 520 shares at an exercise price of $4.55 per share. These options vest 25% after nine months and monthly thereafter over 36 months. All grants were approved by Jaguar's Compensation Committee and are subject to continued employment.
Jaguar Health (NASDAQ:JAGX) has closed a previously announced private placement, raising approximately $3.448 million through convertible promissory notes. The notes, priced at-the-market under Nasdaq rules, have a 3-month maturity and 6% annual interest rate, with immediate conversion options into common stock.
The private placement included participation from company executives, including CEO Lisa Conte, board members, and selected institutional and accredited investors. The deal also included unregistered warrants exercisable immediately with a five-year expiration term. H.C. Wainwright & Co. served as the exclusive placement agent.
The company plans to use the net proceeds for working capital and general corporate purposes, particularly focusing on upcoming Q2 2025 catalysts related to crofelemer development for rare diseases and cancer therapy-related diarrhea.
Jaguar Health (NASDAQ:JAGX) reported strong financial results for 2024, with total net revenue reaching $11.7 million, marking a 20% increase from $9.8 million in 2023. The company's Q4 2024 revenue was $3.5 million, up 13% from Q3 2024 and 53% from Q4 2023.
Prescription products revenue (Mytesi, Gelclair, and Canalevia-CA1) grew 19% to $11.5 million in 2024. Mytesi prescription volume increased by 3.9% year-over-year. The company reduced its operating loss by $3.5 million to $30.8 million in 2024, while net loss decreased by $2.8 million to $38.5 million.
Research and Development expenses decreased by $2.1 million to $16.5 million, while Sales and Marketing expenses increased by $1.2 million to $7.7 million. The company expects first results from proof-of-concept trials for crofelemer in rare diseases in Q2 2025.
Jaguar Health (NASDAQ:JAGX) has released results from a survey of 27 board-certified veterinary oncologists regarding Canalevia-CA1, their FDA conditionally approved treatment for chemotherapy-induced diarrhea (CID) in dogs.
Key findings show that 83.33% of surveyed oncologists emphasized the importance of Canalevia-CA1 being a non-antimicrobial treatment. Additionally, 62.5% expressed concerns about antimicrobial resistance with metronidazole, while 66.66% rated CID as having a moderate to large negative impact on dogs' cancer treatment adherence and quality of life.
Canalevia-CA1 is the first and only FDA-approved treatment for CID in dogs and is available through major veterinary distributors including Chewy. Jaguar Health is now seeking partners to expand the drug's indication for treating general, non-infectious diarrhea in dogs, targeting an estimated six million annual cases in the U.S.
Jaguar Health (NASDAQ:JAGX) has secured a Type C Meeting with the FDA in Q2 2025 to discuss the Phase 3 OnTarget trial results for Mytesi (crofelemer) in breast cancer patients. The trial focused on preventing diarrhea in adults with solid tumors receiving targeted therapy with or without standard chemotherapy.
While the overall trial did not meet its primary endpoint across all tumor types, the breast cancer subgroup, comprising 183 of 287 participants, showed statistically significant responder analysis results. The study demonstrated that crofelemer prophylaxis resulted in a greater proportion of monthly responders for diarrhea improvement compared to placebo in breast cancer patients.
A late-breaker abstract with additional significant results has been submitted to the Multinational Association of Supportive Care in Cancer (MASCC) for their June 2025 Annual Meeting. The American Cancer Society projects 316,950 new breast cancer cases in US women in 2025.
Jaguar Health (NASDAQ:JAGX) has announced two upcoming investor events: a virtual presentation at the Emerging Growth Conference on March 27, 2025, and an investor webcast on March 31, 2025. The company plans to file its annual report on Form 10-K for the year ended December 31, 2024, on March 31, 2025.
CEO Lisa Conte highlighted that several key catalysts are expected in Q2 2025, primarily related to crofelemer development for rare diseases and cancer therapy-related diarrhea, which the company believes could enhance value.
The Emerging Growth Conference presentation is scheduled for March 27 from 3:40-3:50 PM ET, while the investor webcast will take place on March 31 at 8:30 AM ET to review Q4 2024 financials and provide corporate updates.
Jaguar Health (NASDAQ:JAGX) has secured a $3.448 million bridge financing through convertible promissory notes in a private placement priced at-the-market under Nasdaq rules. The company's CEO Lisa Conte, three board members, seven C-suite executives, and selected institutional and accredited investors participated in the financing.
The notes feature a 3-month maturity with a 6% annual interest rate and are immediately convertible into common stock. Additionally, investors will receive unregistered warrants exercisable immediately with a five-year expiration term. The offering is expected to close around March 27, 2025.
H.C. Wainwright & Co. serves as the exclusive placement agent. The proceeds will be used for working capital and general corporate purposes. The securities are being offered under Section 4(a)(2) of the Securities Act and Regulation D, with the company agreeing to file a resale registration statement for the underlying shares.
